CD8A and neoplasm: Studies demonstrate that hypoxia inhibitors can reverse hypoxia‐associated immune exclusion by normalizing tumor vasculature and enhancing CD8+ T cell infiltration.[36, 37] Integrating HIF inhibitors with ICIs may thus rescue immunotherapy efficacy in Cluster 2 patients.